MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
暂无分享,去创建一个
J. Carew | Steffan T Nawrocki | Patrick Griffin | Kevin R Kelly | Jennifer S Carew | K. Kelly | S. Nawrocki | Patrick T. Griffin
[1] D. C. Dias,et al. Nedd8 on cullin: building an expressway to protein destruction , 2004, Oncogene.
[2] J. Wade Harper,et al. Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.
[3] A. Haas,et al. The mechanism of ubiquitin activating enzyme. A kinetic and equilibrium analysis. , 1982, The Journal of biological chemistry.
[4] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[5] V. Chau,et al. Nedd8 Modification of Cul-1 Activates SCFβTrCP-Dependent Ubiquitination of IκBα , 2000, Molecular and Cellular Biology.
[6] Yi Sun,et al. The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme , 2012, PloS one.
[7] A. Ciechanover,et al. Narrative Review: Protein Degradation and Human Diseases: The Ubiquitin Connection , 2006, Annals of Internal Medicine.
[8] E. Lightcap,et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[9] E. Yeh,et al. Identification of NEDD8-conjugation site in human cullin-2. , 1999, Biochemical and biophysical research communications.
[10] Anjanabha Saha,et al. Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation , 2008, Molecular cell.
[11] Keiji Tanaka,et al. Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. , 2004, Current protein & peptide science.
[12] M. Roussel,et al. E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. , 2009, Molecular cell.
[13] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[14] F. Melchior,et al. Concepts in sumoylation: a decade on , 2007, Nature Reviews Molecular Cell Biology.
[15] Aaron Ciechanover,et al. The ubiquitin–proteasome pathway: on protein death and cell life , 1998, The EMBO journal.
[16] M. Petroski,et al. The ubiquitin system, disease, and drug discovery , 2008, BMC Biochemistry.
[17] S. Todo,et al. TRIM40 promotes neddylation of IKKγ and is downregulated in gastrointestinal cancers. , 2011, Carcinogenesis.
[18] M. Hochstrasser,et al. Origin and function of ubiquitin-like proteins , 2009, Nature.
[19] Kongthawat Chairatvit,et al. Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma , 2007, Molecular and Cellular Biochemistry.
[20] Jidong Liu,et al. NEDD8 modification of CUL1 dissociates p120(CAND1), an inhibitor of CUL1-SKP1 binding and SCF ligases. , 2002, Molecular cell.
[21] Mark Manfredi,et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. , 2010, Blood.
[22] H. Suzuki,et al. NEDD8 recruits E2‐ubiquitin to SCF E3 ligase , 2001, The EMBO journal.
[23] A. Ciechanover,et al. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Wade Harper,et al. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways , 2009, Nature Reviews Molecular Cell Biology.
[25] Jeffrey J. Jones,et al. A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins. , 2008, Journal of proteome research.
[26] R. Neve,et al. The Amyloid Precursor Protein-binding Protein APP-BP1 Drives the Cell Cycle through the S-M Checkpoint and Causes Apoptosis in Neurons* , 2000, The Journal of Biological Chemistry.
[27] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[28] Hui Zhang,et al. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. , 2002, Molecular cell.
[29] A. Hershko,et al. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle* , 2005, Cell Death and Differentiation.
[30] A. Hershko,et al. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[31] J. Laubach,et al. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia , 2009, Leukemia & lymphoma.
[32] Francis J Giles,et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. , 2010, Blood.
[33] P. Robinson,et al. E3 ubiquitin ligases. , 2005, Essays in biochemistry.
[34] Michele Cavo,et al. Proteasome inhibitors in multiple myeloma: 10 years later. , 2012, Blood.
[35] Daniel C. Scott,et al. Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation , 2008, Cell.
[36] J. Toth,et al. A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924. , 2012, Cell reports.
[37] E. Yeh,et al. Characterization of NEDD8, a Developmentally Down-regulated Ubiquitin-like Protein* , 1997, The Journal of Biological Chemistry.
[38] L. Kay,et al. Novel proteasome inhibitors to overcome bortezomib resistance. , 2011, Journal of the National Cancer Institute.
[39] W. Kaelin,et al. An intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells , 2002, EMBO reports.
[40] Bhuvanesh Singh,et al. SCCRO (DCUN1D1) Is an Essential Component of the E3 Complex for Neddylation* , 2008, Journal of Biological Chemistry.
[41] A. Ciechanover. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin–proteasome system and onto human diseases and drug targeting* , 2005, Cell Death and Differentiation.
[42] E. Yeh,et al. Identification of the Activating and Conjugating Enzymes of the NEDD8 Conjugation Pathway* , 1999, The Journal of Biological Chemistry.
[43] D. Ribatti,et al. Bortezomib as an antitumor agent. , 2006, Current pharmaceutical biotechnology.
[44] Raymond J. Deshaies,et al. Function and regulation of cullin–RING ubiquitin ligases , 2005, Nature Reviews Molecular Cell Biology.
[45] B. Schulman,et al. Expression, purification, and characterization of the E1 for human NEDD8, the heterodimeric APPBP1-UBA3 complex. , 2005, Methods in enzymology.
[46] R. Deshaies,et al. In vitro reconstitution of SCF substrate ubiquitination with purified proteins. , 2005, Methods in enzymology.
[47] Tommer Ravid,et al. Diversity of degradation signals in the ubiquitin–proteasome system , 2008, Nature Reviews Molecular Cell Biology.
[48] E. Brambilla,et al. Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. , 2007, The Journal of pathology.
[49] Y. Saeki,et al. Direct interactions between NEDD8 and ubiquitin E2 conjugating enzymes upregulate cullin-based E3 ligase activity , 2007, Nature Structural &Molecular Biology.
[50] N. Munshi,et al. Latest advances and current challenges in the treatment of multiple myeloma , 2012, Nature Reviews Clinical Oncology.
[51] S. Elledge,et al. Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex , 2002, Nature.
[52] Kenneth P Nephew,et al. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. , 2003, Molecular endocrinology.
[53] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[54] A. Ciechanover,et al. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. , 2009, Annual review of pharmacology and toxicology.
[55] David W. Miller,et al. The structure of the APPBP1-UBA3-NEDD8-ATP complex reveals the basis for selective ubiquitin-like protein activation by an E1. , 2003, Molecular cell.
[56] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[57] A. Haas,et al. Conservation in the Mechanism of Nedd8 Activation by the Human AppBp1-Uba3 Heterodimer* , 2003, Journal of Biological Chemistry.
[58] Ping Li,et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. , 2010, Molecular cell.
[59] Anindya Dutta,et al. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.
[60] S. Keir,et al. Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.
[61] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[62] D. Kuhn,et al. Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade , 2008, Clinical Cancer Research.
[63] Hua Li,et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. , 2012, Cancer research.
[64] Ivan Dikic,et al. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. , 2012, Annual review of biochemistry.
[65] U. Narayanan,et al. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. , 2011, Cancer research.
[66] J. Andersen,et al. The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe? , 2006, Cytokine & growth factor reviews.
[67] Keiji Tanaka,et al. Covalent modification of all members of human cullin family proteins by NEDD8 , 1999, Oncogene.
[68] N. Munshi,et al. Bortezomib in the front-line treatment of multiple myeloma , 2008, Expert Review of Anticancer Therapy.
[69] Yi Sun,et al. Targeting E3 Ubiquitin Ligases for Cancer Therapy , 2003, Cancer biology & therapy.
[70] D. McMillin,et al. Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma , 2012, Molecular Cancer Therapeutics.
[71] M. Hochstrasser,et al. Modification of proteins by ubiquitin and ubiquitin-like proteins. , 2006, Annual review of cell and developmental biology.
[72] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[73] M. Huang,et al. Inhibition of the Nedd8 System Sensitizes Cells to DNA Interstrand Cross-linking Agents , 2012, Molecular Cancer Research.
[74] M. Tyers,et al. Dcn1 functions as a scaffold-type E3 ligase for cullin neddylation. , 2008, Molecular cell.
[75] C. Hill,et al. Crystal Structure of the Human Ubiquitin-like Protein NEDD8 and Interactions with Ubiquitin Pathway Enzymes* , 1998, The Journal of Biological Chemistry.
[76] Usha Narayanan,et al. Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. , 2012, Cancer cell.